7 March 2016 - Deborah Wilkes
Archived
RB is facing a class action in Australia following the recent court ruling that four of the company's Nurofen products had made "misleading" specific-pain claims. In a separate development, RB has withdrawn television advertising for Nurofen Express in the UK following an investigation by the Advertising Standards Authority (ASA).
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.